Letters A/H1N1 flu pandemic

Roche responds

BMJ 2009; 339 doi: https://doi.org/10.1136/bmj.b3758 (Published 14 September 2009) Cite this as: BMJ 2009;339:b3758
  1. Michelle Rashford, medical director1
  1. 1Roche Products, Welwyn Garden City, Hertfordshire AL7 1TW
  1. michelle.rashford{at}roche.com

    The use of oseltamivir (Tamiflu) in children and the development of resistance from widespread usage have been much debated.1

    Antiviral treatments are currently the only available therapeutic option to prevent and treat infection with the A/H1N1 flu virus. The product summary for oseltamivir shows that it is effective and well tolerated in children.

    The …

    View Full Text

    Sign in

    Log in through your institution

    Subscribe